Literature DB >> 11060356

Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism.

J D Medh1, G L Fry, S L Bowen, S Ruben, H Wong, D A Chappell.   

Abstract

Apolipoprotein E (apoE) is the primary recognition signal on triglyceride-rich lipoproteins responsible for interacting with low density lipoprotein (LDL) receptors and LDL receptor-related protein (LRP). It has been shown that lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) promote receptor-mediated uptake and degradation of very low density lipoproteins (VLDL) and remnant particles, possibly by directly binding to lipoprotein receptors. In this study we have investigated the requirement for apoE in lipase-stimulated VLDL degradation. We compared binding and degradation of normal and apoE-depleted human VLDL and apoE knockout mouse VLDL in human foreskin fibroblasts. Surface binding at 37 degrees C of apoE knockout VLDL was greater than that of normal VLDL by 3- and 40-fold, respectively, in the presence of LPL and HTGL. In spite of the greater stimulation of surface binding, lipase-stimulated degradation of apoE knockout mouse VLDL was significantly lower than that of normal VLDL (30, 30, and 80%, respectively, for control, LPL, and HTGL treatments). In the presence of LPL and HTGL, surface binding of apoE-depleted human VLDL was, respectively, 40 and 200% of normal VLDL whereas degradation was, respectively, 25 and 50% of normal VLDL. LPL and HTGL stimulated degradation of normal VLDL in a dose-dependent manner and by a LDL receptor-mediated pathway. Maximum stimulation (4-fold) was seen in the presence LPL (1 microgram/ml) or HTGL (3 microgram/ml) in lovastatin-treated cells. On the other hand, degradation of apoE-depleted VLDL was not significantly increased by the presence of lipases even in lovastatin-treated cells. Surface binding of apoE-depleted VLDL to metabolically inactive cells at 4 degrees C was higher in control and HTGL-treated cells, but unchanged in the presence of LPL. Degradation of prebound apoE-depleted VLDL was only 35% as efficient as that of normal VLDL. Surface binding of apoE knockout or apoE-depleted VLDL was to heparin sulfate proteoglycans because it was completely abolished by heparinase treatment. However, apoE appears to be a primary determinant for receptor-mediated VLDL degradation. Our studies suggest that overexpression of LPL or HTGL may not protect against lipoprotein accumulation seen in apoE deficiency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060356      PMCID: PMC2759277     

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  70 in total

1.  Lipoprotein lipase-mediated uptake of lipoprotein in human fibroblasts: evidence for an LDL receptor-independent internalization pathway.

Authors:  M Fernández-Borja; D Bellido; E Vilella; G Olivecrona; S Vilaró
Journal:  J Lipid Res       Date:  1996-03       Impact factor: 5.922

2.  Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro.

Authors:  J D Medh; S L Bowen; G L Fry; S Ruben; M Andracki; I Inoue; J M Lalouel; D K Strickland; D A Chappell
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

3.  Chinese hamster ovary cells expressing a cell surface-anchored form of hepatic lipase. Characterization of low density lipoprotein and chylomicron remnant uptake and selective uptake of high density lipoprotein-cholesteryl ester.

Authors:  M Komaromy; S Azhar; A D Cooper
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

4.  Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo.

Authors:  P C Rensen; T J van Berkel
Journal:  J Biol Chem       Date:  1996-06-21       Impact factor: 5.157

Review 5.  Triglyceride lipases and atherosclerosis.

Authors:  G Olivecrona; T Olivecrona
Journal:  Curr Opin Lipidol       Date:  1995-10       Impact factor: 4.776

6.  Apolipoprotein E and lipoprotein lipase co-ordinately enhance binding and uptake of chylomicrons by human hepatocytes.

Authors:  W A Mann; N Meyer; W Weber; F Rinninger; H Greten; U Beisiegel
Journal:  Eur J Clin Invest       Date:  1995-11       Impact factor: 4.686

7.  Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors.

Authors:  V S Kashyap; S Santamarina-Fojo; D R Brown; C L Parrott; D Applebaum-Bowden; S Meyn; G Talley; B Paigen; N Maeda; H B Brewer
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

8.  Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase.

Authors:  S Takahashi; J Suzuki; M Kohno; K Oida; T Tamai; S Miyabo; T Yamamoto; T Nakai
Journal:  J Biol Chem       Date:  1995-06-30       Impact factor: 5.157

9.  Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C.

Authors:  H H van Barlingen; H de Jong; D W Erkelens; T W de Bruin
Journal:  J Lipid Res       Date:  1996-04       Impact factor: 5.922

10.  Apolipoprotein B and E basic amino acid clusters influence low-density lipoprotein association with lipoprotein lipase anchored to the subendothelial matrix.

Authors:  U Saxena; B J Auerbach; E Ferguson; J Wölle; Y L Marcel; K H Weisgraber; R A Hegele; C L Bisgaier
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-08       Impact factor: 8.311

View more
  9 in total

1.  ShRNA-mediated gene silencing of lipoprotein lipase improves insulin sensitivity in L6 skeletal muscle cells.

Authors:  Majib Jan; Jheem D Medh
Journal:  Biochem Biophys Res Commun       Date:  2015-04-27       Impact factor: 3.575

Review 2.  Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review.

Authors:  Petter Bjornstad; Robert H Eckel
Journal:  Curr Diab Rep       Date:  2018-10-17       Impact factor: 4.810

3.  Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-I,A-II).

Authors:  Marian C Cheung; Shalamar D Sibley; Jerry P Palmer; John F Oram; John D Brunzell
Journal:  J Lipid Res       Date:  2003-06-01       Impact factor: 5.922

4.  Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice.

Authors:  Dacheng Peng; Richard A Hiipakka; Jing-Tian Xie; Catherine A Reardon; Godfrey S Getz; Shutsung Liao
Journal:  Atherosclerosis       Date:  2009-07-08       Impact factor: 5.162

5.  Down-regulation of lipoprotein lipase increases ABCA1-mediated cholesterol efflux in THP-1 macrophages.

Authors:  Ryoko L Kawashima; Jheem D Medh
Journal:  Biochem Biophys Res Commun       Date:  2014-07-10       Impact factor: 3.575

6.  Maternal loading with very low-density lipoproteins stimulates fetal surfactant synthesis.

Authors:  Alan J Ryan; Jheem D Medh; Diann M McCoy; Ronald G Salome; Rama K Mallampalli
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-08       Impact factor: 5.464

7.  Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice.

Authors:  Kristin I Stanford; Joseph R Bishop; Erin M Foley; Jon C Gonzales; Ingrid R Niesman; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

8.  Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouse.

Authors:  Elena Ulasova; Jessica Perez; Bradford G Hill; Wayne E Bradley; David W Garber; Aimee Landar; Stephen Barnes; Jeevan Prasain; Dale A Parks; Louis J Dell'Italia; Victor M Darley-Usmar
Journal:  Redox Biol       Date:  2013-07-16       Impact factor: 11.799

9.  Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids.

Authors:  Yan Q Chen; Thomas G Pottanat; Robert W Siegel; Mariam Ehsani; Yue-Wei Qian; Eugene Y Zhen; Ajit Regmi; William C Roell; Haihong Guo; M Jane Luo; Ruth E Gimeno; Ferdinand Van't Hooft; Robert J Konrad
Journal:  J Lipid Res       Date:  2020-06-02       Impact factor: 5.922

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.